孕早期胎儿巨膀胱宫内分流术后首年生存、肾功能与并发症的前瞻性队列分析
该前瞻性队列在德国两家产前医学中心纳入40例孕11+0至13+6周、膀胱纵径大于15 mm的胎儿巨膀胱,于不超过孕14+6周行Somatex分流术。围产期生存率为73%(29/40),1岁时生存率为68%(27/40);分流相关并发症发生于22/40对(55%),其中3例(8%)与产前死亡相关或导致产前死亡。
要点
- 孕早期Somatex分流术技术可行,围产期生存率73%、1岁生存率68%。
- 1岁存活儿中96%无需透析,肾功能以正常或轻度受损为主。
- 分流相关并发症发生于55%的孕妇-子代对,8%与产前死亡相关。
核心结论
- 在该前瞻性观察队列中,孕早期膀胱羊水分流术技术可行,且在该 historically 预后不良人群中与首年生存及以正常或轻度受损为主的肾功能相关。
研究设计与样本
- 研究为德国科隆大学医院与波恩大学医院产前医学中心的前瞻性描述性队列分析。
- 纳入标准为孕11+0至13+6周诊断胎儿巨膀胱且膀胱纵径大于15 mm、于不超过孕14+6周行Somatex分流术的单胎妊娠。
- 2019年6月24日至2024年1月23日共40例胎儿接受分流术,中位孕周14+0周(IQR 13+3-14+3)。
主要发现
- 30例(75%)活产,活产中位孕周38+1周(IQR 37+4-39+0)。
- 围产期生存率为73%(29/40),1岁时生存率为68%(27/40)。
- 1例新生儿期安宁疗护中死亡,2例于新生儿期或婴儿早期死亡。
- 分流相关并发症(产前及产后)发生于22/40对(55%),其中3例(8%)与产前死亡相关或导致产前死亡,包括2例未足月胎膜早破和1例宫内死亡。
临床怎么用
- 对于孕11+0至13+6周诊断、膀胱纵径大于15 mm的胎儿巨膀胱,可考虑在不超过孕14+6周行Somatex分流术,但需多学科团队术前咨询。
- 术后需关注分流相关并发症,包括未足月胎膜早破和宫内死亡,并随访至1岁评估生存与肾功能。
局限性
- 研究为描述性前瞻性队列,样本量40例,未设对照组。
- 产后随访按临床需要提供,肾功能以最低血清肌酐评估,未报告其他肾功能指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Congenital lower urinary tract obstruction is a major cause of chronic kidney disease in children. Severe first-trimester megacystis larger than 15 mm is almost invariably associated with poor outcome. Second-trimester vesicoamniotic shunting does not substantially improve survival or kidney function, but evidence from animal models suggests that earlier urinary tract decompression might preserve kidney function. Since 2014, the Somatex shunt has enabled first-trimester vesicoamniotic shunting, with encouraging outcomes. We aimed to prospectively describe survival, kidney function, and morbidity in infants up to 1 year after first-trimester vesicoamniotic shunting with the Somatex shunt. METHODS: We conducted a descriptive analysis of a prospective cohort at the prenatal medicine centres of University Hospital Cologne and University Hospital Bonn (Germany). Singleton pregnancies were eligible if fetal megacystis with a longitudinal bladder diameter greater than 15 mm was diagnosed between gestational ages 11+0 weeks and 13+6 weeks and vesicoamniotic shunting with the Somatex shunt was done no later than gestational age 14+6 weeks. Counselling was provided by a multidisciplinary team before the procedure was done. Prenatal (ultrasonography) and postnatal (care provided according to clinical need) follow-up was provided at the study centres or local hospitals. The primary outcome was perinatal survival (survival to 7 completed days of life). Secondary outcomes were prenatal and 1-year postnatal mortality and morbidity (including kidney function assessed by nadir serum creatinine within the first year of life), recorded from clinical reports and hospital documentation according to predefined criteria. Fisher's exact test was applied to selected categorical comparisons, including differences in prenatal complication rates between surviving and non-surviving infants. The study was registered with the German Clinical Trials Register (DRKS00017779). FINDINGS: Between June 24, 2019, and Jan 23, 2024, 40 fetuses underwent vesicoamniotic shunting at a median gestational age of 14+0 weeks (IQR 13+3-14+3). 30 infants (75%) were born alive at a median gestational age of 38+1 weeks (IQR 37+4-39+0). Perinatal survival was 73% (29 of 40), and survival at age 1 year was 68% (27 of 40). One infant died during neonatal palliative care and two died during the neonatal or early infantile period. Vesicoamniotic shunting-related complications (prenatal and postanatal) occurred in 22 (55%) of 40 pregnant woman-child pairs. Three (8%) complications were associated with or resulted in prenatal death, including two cases of premature prelabour rupture of membranes and one intrauterine death. Of the 27 first year survivors, 26 (96%) did not require dialysis and had a median nadir serum creatinine of 0·21 mg/dL (IQR 0·18-0·33). INTERPRETATION: In this prospective observational cohort, first-trimester vesicoamniotic shunting was technically feasible and associated with survival and predominantly normal or mildly impaired kidney function in the first year of life in a population historically characterised by poor prognosis. FUNDING: University of Cologne.
引用
- Weber EC, Kohl S, Gottschalk I, et al. Survival, kidney function, and complications in the first year of life following intrauterine shunting for first-trimester fetal megacystis (IUS1st): analysis of a prospective observational cohort. Lancet Child Adolesc Health. 2026. PMID: 41831479. doi:10.1016/S2352-4642(26)00011-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。